Kirenol

Synonyms: 奇任醇
Kirenol 是一种具有口服活性的二萜类化合物,作为细胞凋亡 (apoptosis) 诱导与信号通路调控剂,其针对 CK2 的靶标 Kd 为 5.47 μM,可促进 Bid 裂解为 tBid,调控 Bax、Bcl-2、p53、p21 的蛋白水平/磷酸化过程,并在癌细胞中诱导不依赖半胱天冬酶的细胞凋亡、S 期细胞周期阻滞、ROS 积累及细胞毒性,同时可激活 CK2/AKT 与 AMPK-mTOR-ULK1 通路,抑制 NF-κB、TGF-β/Smads 及 NLRP3 炎症小体信号传导,调控 GSK3β、BMP 与 Wnt/β-catenin 通路,诱导自噬、线粒体自噬和成骨细胞分化,促进线粒体融合,并具有抗氧化、抗炎、抗纤维化、肾保护、心脏保护、神经保护及镇痛作用,可用于慢性髓系白血病、缺血性脑卒中、糖尿病肾病、心力衰竭、急性肺损伤和骨质疏松症的相关研究。
产品编号: MS-H24853 纯度: 99.82% CAS No.: 52659-56-0 分子式: C20H34O4 分子量: 338.48
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Kirenol 是一种具有口服活性的二萜类化合物,作为细胞凋亡 (apoptosis) 诱导与信号通路调控剂,其针对 CK2 的靶标 Kd 为 5.47 μM,可促进 Bid 裂解为 tBid,调控 Bax、Bcl-2、p53、p21 的蛋白水平/磷酸化过程,并在癌细胞中诱导不依赖半胱天冬酶的细胞凋亡、S 期细胞周期阻滞、ROS 积累及细胞毒性,同时可激活 CK2/AKT 与 AMPK-mTOR-ULK1 通路,抑制 NF-κB、TGF-β/Smads 及 NLRP3 炎症小体信号传导,调控 GSK3β、BMP 与 Wnt/β-catenin 通路,诱导自噬、线粒体自噬和成骨细胞分化,促进线粒体融合,并具有抗氧化、抗炎、抗纤维化、肾保护、心脏保护、神经保护及镇痛作用,可用于慢性髓系白血病、缺血性脑卒中、糖尿病肾病、心力衰竭、急性肺损伤和骨质疏松症的相关研究。

生物实验数据

生物活性 Kirenol is an orally active diterpenoid compound that acts as an apoptosis inducer and signaling pathway regulator with a target Kd of 5.47 μM for CK2; it promotes Bid cleavage to tBid, regulates the protein levels/phosphorylation of Bax, Bcl-2, p53, and p21, and induces caspase-independent apoptosis, S-phase cell cycle arrest, ROS accumulation, and cytotoxicity in cancer cells, while activating the CK2/AKT and AMPK-mTOR-ULK1 pathways, inhibiting NF-κB, TGF-β/Smads, and NLRP3 inflammasome signaling, and modulating the GSK3β, BMP, and Wnt/β-catenin pathways; it also induces autophagy, mitophagy, and osteoblast differentiation, promotes mitochondrial fusion, and exhibits antioxidant, anti-inflammatory, anti-fibrotic, renoprotective, cardioprotective, neuroprotective, and analgesic effects, making it useful for research on chronic myeloid leukemia, ischemic stroke, diabetic nephropathy, heart failure, acute lung injury, and osteoporosis.
体外研究
(In Vitro)

Kirenol (10-40 μg/mL;24-72 h) 可时间和剂量依赖性地强效抑制人慢性粒细胞白血病 K562 细胞的增殖,其 IC50 值在 24 h 时为 53.05 μg/mL、48 h 时为 18.19 μg/mL、72 h 时为 15.08 μg/mL。
Kirenol (10-40 μg/mL;24 h) 可在人慢性粒细胞白血病 K562 细胞中诱导剂量依赖性凋亡,凋亡率范围为 8.29% 至 51.85%。
Kirenol (40 μg/mL;12-48 h) 可在 12、24 和 48 h 内以时间依赖的方式诱导人慢性髓系白血病 K562 细胞的线粒体膜电位丧失。
Kirenol (40 μg/mL; 12-48 h) 可在 12、24 和 48 h 内以时间依赖的方式诱导人慢性髓系白血病 K562 细胞中 ROS 的积累。
Kirenol (40 μg/mL; 12-48 h) 可调控人慢性粒细胞白血病 K562 细胞中 Bcl-2 家族蛋白的表达,在 12、24 和 48 h 时降低 Bcl-2 水平并升高 Bax 和 tBid 水平;上调 p53(Ser 6 和 Ser 37) 的磷酸化水平及 p21 蛋白的表达,且不改变总 p53 的水平。
Kirenol (10-40 μg/mL;48 h) 可在人慢性髓系白血病 K562 细胞中诱导呈剂量依赖性的 S 期细胞周期阻滞。
Kirenol (含 1.25-5% Kirenol 的血清;于 TBHP 处理前预处理 24 h) 可通过调控凋亡蛋白、减少 ROS 并恢复抗氧化/氧化应激标志物的平衡,在 TBHP 损伤的 HT22 细胞中发挥抗凋亡与抗氧化作用。
Kirenol (含 1.25-5% Kirenol 的血清;TBHP 处理前预处理 24 h) 可在 TBHP 损伤的 HT22 细胞中维持线粒体功能,促进 Opa1 介导的线粒体融合,逆转线粒体碎裂、提升 ATP 生成水平、恢复 MMP 并上调 Opa1 的表达。
Kirenol (10-80 μM 预孵育 30 min 后与 30 mM 葡萄糖共处理 24 h;20 μM 预孵育 30 min 后与 10 ng/mL TGF-β1 共处理 24 h) 可抑制小鼠原代系膜细胞中 TGF-β/Smads 通路的活化,并减少细胞外基质蛋白的积累。
Kirenol (20 μM;Ang II 刺激 24 h 前预孵育 3 h) 可通过增强线粒体自噬抑制小鼠骨髓来源巨噬细胞中 Ang II 诱导的 NLRP3 炎症小体活化及线粒体活性氧生成,而线粒体自噬抑制剂可逆转上述效应。
Kirenol (50-200 μg/mL;LPS 刺激后 24 h) 可呈剂量依赖性地抑制 LPS 刺激的 A549 细胞中 TNF-α mRNA 的表达。
Kirenol (50-200 μg/mL;LPS 刺激后 24 h) 可呈剂量依赖性地增强 LPS 刺激的 A549 细胞的自噬水平,表现为 LC3-II 蛋白水平升高、p62 蛋白水平降低。
Kirenol (200 μg/mL;LPS 刺激后 24 h) 可激活 LPS 刺激的 A549 细胞中的 AMPK-mTOR-ULK1 通路,表现为 p-AMPK 和 p-ULK1 蛋白水平升高、p-mTOR 蛋白水平降低。
Kirenol (10-40 μM;3 天) 可呈剂量依赖性地上调 MC3T3-E1 细胞中关键成骨细胞分化标志物 (ALP、ColA1、OPN) 的 mRNA 表达;在 40 μM 处理 3 天后,上述标志物的表达水平分别显著提升 67.8%、40.0% 和 67.7%。
Kirenol (10-40 μM;作用 3 天) 可通过上调 BMP2、Runx2 及 Osx 的 mRNA 表达,以剂量依赖的方式激活 MC3T3-E1 细胞中的 BMP 信号通路。

Apoptosis Analysis

Cell Line: human chronic myeloid leukemia K562 cells
Concentration: 40 μg/mL
Incubation Time: 24 h
Result: Induced marked nuclear condensation and fragmentation in K562 cells, as indicated by fluorescent staining.

Western Blot Analysis

Cell Line: human chronic myeloid leukemia K562 cells
Concentration: 40 μg/mL
Incubation Time: 12, 24, 48 h
Result: Caused a significant decrease in mitochondrial cytochrome c levels at 12 and 24 h. Induced a marked increase in cytosolic cytochrome c levels at 24 h.
Decreased Bcl-2 protein levels at 24 and 48 h. Upregulated Bax and tBid (cleaved Bid) protein levels at 12, 24, and 48 h.\nIncreased phosphorylation of p53 at Ser 6 and Ser 37 at 24 and 48 h, with no change in total p53 levels. Significantly increased p21 protein levels at 12, 24, and 48 h.

Cell Cycle Analysis

Cell Line: human chronic myeloid leukemia K562 cells
Concentration: 10-40 μg/mL
Incubation Time: 48 h
Result: Induced dose-dependent S-phase cell cycle arrest, with S-phase population increasing from 48.99% (untreated) to 52.89% (10 μg/mL), 56.05% (20 μg/mL), and 70.04% (40 μg/mL).

Western Blot Analysis

Cell Line: Primary mouse mesangial cells
Concentration: 10-80 μM
Incubation Time: 24 h (co-treatment); 30 min (pre-incubation)
Result: Reduced high glucose-induced increases in fibronectin and collagen IV levels. Inhibited high glucose-induced phosphorylation of Smad2/3. Suppressed TGF-β1-induced phosphorylation of Smad2/3. Attenuated TGF-β1-induced increases in fibronectin and collagen IV levels. Did not alter baseline levels of these proteins when treated alone at 20 μM.

Real Time qPCR

Cell Line: A549 (LPS-challenged acute lung injury cell model)
Concentration: 50-200 μg/mL
Incubation Time: 1 h pre-incubation, then 24 h with LPS
Result: Dose-dependently reduced LPS-induced TNF-α mRNA expression.

Immunofluorescence

Cell Line: A549 (LPS-challenged acute lung injury cell model)
Concentration: 200 μg/mL
Incubation Time: 1 h pre-incubation, then 24 h with LPS
Result: Increased the number of LC3 dots per cell relative to LPS-only treated cells.
Decreased p62 fluorescence intensity per cell relative to LPS-only treated cells.
Decreased mTOR fluorescence intensity per cell relative to LPS-only treated cells.
Decreased p-mTOR fluorescence intensity per cell relative to LPS-only treated cells.

Cell Viability Assay

Cell Line: MC3T3-E1 pre-osteoblastic cells
Concentration: 10-40 μM
Incubation Time: 24 h
Result: Showed no significant cytotoxicity at 10, 20, and 40 μM.

RT-PCR

Cell Line: MC3T3-E1 pre-osteoblastic cells undergoing osteoblast differentiation
Concentration: 10-40 μM
Incubation Time: 3 days
Result: Increased mRNA expression of ALP, type I collagen (ColA1), and osteopontin (OPN) in a dose-dependent manner; increased ALP mRNA expression by 67.8%, ColA1 by 40.0%, and OPN by 67.7% at 40 μM compared to control.
Increased mRNA expression of osteoprotegerin (OPG), while decreased receptor activator of nuclear factor kappa B ligand (RANKL) mRNA expression, resulting in an increased OPG/RANKL ratio.\nSignificantly increased mRNA expression of BMP2, runt-related transcription factor 2 (Runx2), and osterix (Osx) in a dose-dependent manner.
Significantly increased mRNA expression of low density lipoprotein receptor related protein 5 (LRP5), disheveled 2 (DVL2), β-catenin, and cyclin D1 (CCND1) in a dose-dependent manner.
体内研究
(In Vivo)

Kirenol (1.25-5 mg/kg;腹腔注射;每日 1 次;连续 7 天) 在 MCAO/R 大鼠中呈现剂量依赖性神经保护作用:5 mg/kg 剂量下可使脑梗死体积减少约 55%,同时改善神经功能、减轻氧化应激,并通过激活 CK2/AKT 通路促进 Opa1 介导的线粒体融合。
Kirenol (2 mg/kg;灌胃;每日给药;连续 3 个月) 可通过使 Smad2/3 的磷酸化水平降低至 0.64 倍、NF-κB 的磷酸化水平降低至 0.43 倍、恢复 IκBα 水平、减少细胞外基质 (ECM) 蓄积与炎性细胞因子表达,以及改善肾脏结构和功能标志物,缓解雄性 C57BL/6J 小鼠的糖尿病肾病。
Kirenol (50 mg/kg; i.p.; daily; starting 1 day pre-surgery until study end) 可通过改善心脏功能、减轻心肌肥厚与纤维化、抑制炎症反应及增强巨噬细胞线粒体自噬,在压力过载诱导的心力衰竭模型中发挥心脏保护作用;而线粒体自噬受抑制时,上述获益效应会被消除。
Kirenol (0.1-0.5% (w/w);经皮给药;单次涂抹 0.3 g 乳膏) 可剂量依赖性地抑制角叉菜胶诱导的急性足肿胀,并降低局部促炎细胞因子 (IL-1β、TNF-α) 水平。
Kirenol (100 mg/kg; i.p.; daily; 7 days) 可通过增强自噬和抑制炎症作用显著减轻 LPS 诱导的 Balb/c 小鼠急性肺损伤,其佐证包括炎性细胞因子水平降低、肺组织病理学改善以及肺水肿和白细胞浸润减少。

Animal Model: Sprague-Dawley (male, 200-240 g, ischemic stroke model via MCAO/R)
Dosage: 1.25 mg/kg; 2.5 mg/kg; 5 mg/kg
Administration: i.p.; daily; 7 days
Result: Significantly reduced modified Neurological Severity Scores (mNSS), increased paw grip tension, and reduced right turn frequency on days 5 and 7 post-treatment.
Significantly reduced cerebral infarct volume, with the 5 mg/kg group showing reduction to ~18% infarct volume (vs ~40% in MCAO controls), corresponding to up to ~55% reduction.
Reduced neuronal nuclear contraction and cell spacing in the ischemic cortex, with improved cell structure organization.
Significantly increased levels of superoxide dismutase (SOD), glutathione (GSH), glutathione peroxidase (GPx), and SOD2 protein expression, while significantly reducing levels of malondialdehyde (MDA) and lactate dehydrogenase (LDH) in peri-infarct brain tissue.\nSignificantly increased optic atrophy 1 (Opa1) protein expression without altering levels of Fis1, Drp1, MFN1, MFN2.\nSignificantly increased CK2 protein levels and AKT phosphorylation (p-AKT/AKT ratio) in peri-infarct brain tissue.
Animal Model: C57BL/6J (male, ~20 g, diabetic nephropathy induced via 2 months high-fat diet + 5 consecutive days 100 mg/kg streptozotocin i.p. injection)
Dosage: 2 mg/kg
Administration: p.o.; daily; 3 months
Result: Did not lower blood glucose but improved the kidney/body weight ratio.
Ameliorated serum creatinine and blood urea nitrogen levels.
Alleviated diabetes-induced mesangial expansion, focal interstitial inflammation, glomerular atrophy, and glomerular sclerosis.
Reduced glomerular basement membrane thickness and podocyte foot process fusion.
Decreased phosphorylation of Smad2/3 by 0.64-fold, and reduced accumulation of fibronectin (FN) and collagen IV (Col IV) by 0.58-fold and 0.35-fold, respectively.
Restored IκBα expression to normal levels.
Decreased phosphorylation of NF-κB by 0.43-fold.
Reduced IL-6 and TNF-α expression by 0.57-fold and 0.46-fold, respectively.
Reduced FN-positive area and collagen fiber accumulation in renal tissue.
Animal Model: C57BL/6J (8-week-old male)
Dosage: 50 mg/kg
Administration: i.p.; daily; starting 1 day pre-surgery until study end
Result: Increased left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) compared to vehicle-treated TAC mice.
Reduced end-diastolic left ventricular internal dimension (LVIDd) compared to vehicle-treated TAC mice.
Reduced mRNA levels of cardiac stress biomarkers ANP and BNP compared to vehicle-treated TAC mice.
Lowered heart weight to body weight (HW/BW) ratios compared to vehicle-treated TAC mice.
Decreased cardiomyocyte cross-sectional area compared to vehicle-treated TAC mice.
Reduced cardiac collagen deposition (fibrosis) measured by Masson's trichrome staining compared to vehicle-treated TAC mice.
Lowered mRNA expression of fibrosis markers α-SMA, COL1, and COL3 compared to vehicle-treated TAC mice.
Decreased cardiac infiltration of CD11b+F4/80+ macrophages compared to vehicle-treated TAC mice.
Reduced NLRP3 protein expression in heart tissue compared to vehicle-treated TAC mice.
Lowered serum levels of pro-inflammatory cytokines TNF-α, IL-6, IL-18, and IL-1β compared to vehicle-treated TAC mice.
Animal Model: Wistar rats (male, SPF, 250-300 g)
Dosage: 0.1% (w/w); 0.2% (w/w); 0.3% (w/w); 0.4% (w/w); 0.5% (w/w)
Administration: topical; single application of 0.3 g cream
Result: Produced 36.87%, 40.02%, 39.01%, and 42.62% reduction in paw edema at 1, 2, 3, and 4 hours post-carrageenan injection, respectively, with statistically significant differences vs. base cream at all time points.
Produced 48.88%, 43.01%, 42.77%, and 47.20% reduction in paw edema at 1, 2, 3, and 4 hours post-carrageenan injection, respectively, with statistically significant differences vs. base cream at all time points.
Produced 57.28%, 55.34%, 46.21%, and 48.90% reduction in paw edema at 1, 2, 3, and 4 hours post-carrageenan injection, respectively, with statistically significant differences vs. base cream.
Produced 65.37%, 65.21%, 61.25%, and 64.21% reduction in paw edema at 1, 2, 3, and 4 hours post-carrageenan injection, respectively, with statistically significant differences vs. base cream; this anti-inflammatory effect was similar to that of 0.5% piroxicam gel at 4 hours post-carrageenan injection.
Produced 81.09%, 74.82%, 76.31%, and 76.78% reduction in paw edema at 1, 2, 3, and 4 hours post-carrageenan injection, respectively, with statistically significant differences vs. base cream; this anti-inflammatory effect was similar to that of 0.5% piroxicam gel at 4 hours post-carrageenan injection.
Significantly reduced carrageenan-induced increases in IL-1β and TNF-α levels in subcutaneous plantar tissue.
Animal Model: Balb/c (6-8 weeks old, 18-22 g, 20 female, 20 male, LPS-induced ALI)
Dosage: 100 mg/kg
Administration: i.p.; daily; 7 consecutive days
Result: Significantly decreased LPS-induced serum levels of IL-1β, IL-6, and TNF-α.
Significantly decreased LPS-induced lung homogenate levels of IL-1β, IL-6, and TNF-α.
Increased lung tissue LC3-II protein expression and decreased lung tissue p62 protein expression compared to LPS-only mice.
Attenuated LPS-induced lung pathological injuries (including alveolar collapse, stromal hemorrhage, pulmonary edema, and inflammatory cell infiltration).
Reduced lung wet/dry weight ratio, decreased bronchoalveolar lavage fluid (BALF) protein concentration, reduced total BALF cell count, lowered BALF neutrophil percentage, and decreased lung myeloperoxidase (MPO) activity compared to LPS-only mice.
性状 固体
颜色 Off-white to light yellow

化学信息

分子量 338.48
分子式 C20H34O4
CAS No. 52659-56-0
别名 奇任醇

储存&溶解度

体内实验配方
10% DMSO+90% Saline: 10 mg/mL (29.54 mM), Solution.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2.5 mg/mL (7.39 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

-20°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (295.44 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

H2O 中的溶解度 : < 0.1 mg/mL (insoluble)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.9544 mL14.7719 mL29.5438 mL73.8596 mL
5 mM0.5909 mL2.9544 mL5.9088 mL14.7719 mL
10 mM0.2954 mL1.4772 mL2.9544 mL7.3860 mL
15 mM0.1970 mL0.9848 mL1.9696 mL4.9240 mL
20 mM0.1477 mL0.7386 mL1.4772 mL3.6930 mL
25 mM0.1182 mL0.5909 mL1.1818 mL2.9544 mL
30 mM0.0985 mL0.4924 mL0.9848 mL2.4620 mL
40 mM0.0739 mL0.3693 mL0.7386 mL1.8465 mL
50 mM0.0591 mL0.2954 mL0.5909 mL1.4772 mL
60 mM0.0492 mL0.2462 mL0.4924 mL1.2310 mL
80 mM0.0369 mL0.1846 mL0.3693 mL0.9232 mL
100 mM0.0295 mL0.1477 mL0.2954 mL0.7386 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础